Skip to main content

Advertisement

Table 3 Significant associations between the plasma levels of exosomal miRNAs and clinicopathological/risk parameters (categorial variables)

From: Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Clinical/risk factors miRNAs* All BC patients HER2-positive patients TNBC patients
p(t test)** p(t test)** p(t test)**
Age (< 50, ≥ 50) miR-20a 0.011
miR-30c 0.038
miR-99b 0.006 0.002
miR-106b 0.024
miR-145 0.015 0.040
miR-150 0.008 0.015
miR-185 0.035
miR-202 0.046
miR-301 0.019 0.032
miR-891a 0.007 0.010
Nodal status (N0, N+) miR-16 0.023
miR-328 0.019
miR-660 0.016
Tumor size (T1–2, T3–4) miR-185 0.040
miR-199a-3p 0.034
miR-374 0.030
miR-376a 0.004
miR-382 0.031 0.014
miR-410 0.038
miR-433 0.037
miR-628-5p 0.041
Grading (G1–2, G3) miR-16 0.033
miR-20a 0.024 0.032
miR-30c 0.023
miR-155 0.038
miR-193b 0.028
miR-422a 0.010
miR-628-5p 0.005
Lymphocyte predominant breast cancer (neg, pos) miR-148a 0.036
miR-335 0.048
miR-652 0.040
miR-891a 0.050 0.022
  1. Cells filled with “-” denote insignificant correlations
  2. *Only miRNAs are listed which significantly correlate with the clinical parameter in one of the (TNBC and HER2-positive) patient subgroups and/or all patients
  3. **p(t test), Student’s t test